Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

Paul Nathan*, Paolo A. Ascierto, John Haanen, Enrique Espinosa, Lev Demidov, Claus Garbe, Michele Guida, Paul Lorigan, Vanna Chiarion-Sileni, Helen Gogas, Michele Maio, Maria Teresa Fierro, Christoph Hoeller, Patrick Terheyden, Ralf Gutzmer, Tormod K. Guren, Dimitrios Bafaloukos, Piotr Rutkowski, Ruth Plummer, Ashita WaterstonMartin Kaatz, Mario Mandala, Ivan Marquez-Rodas, Eva Muñoz-Couselo, Reinhard Dummer, Elena Grigoryeva, Tina C. Young, Dirk Schadendorf

*Korrespondierende/r Autor/-in für diese Arbeit
15 Zitate (Scopus)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)“. Zusammen bilden sie einen einzigartigen Fingerprint.

Medicine and Dentistry